Thrombocytopenia (fall in the platelet count of >50%) is the most common clinical manifestation of heparin-induced thrombocytopenia (HIT). HIT is due to the heparin-induced formation of IgG antibodies. These antibodies adhere to platelet factor 4 (PF4) on platelet surfaces, resulting in platelet activation and subsequent release of prothrombotic substances, leading to the formation of venous and arterial thrombosis. The risk of developing HIT is approximately ten times higher with UFH treatment, compared to LMWH or fondaparinux treatment.